Gleevec in PAH

Phase III data for Novartis AG's Gleevec imatinib show potential for the tyrosine kinase inhibitor in late-stage pulmonary arterial hypertension. But its second-generation TKI Tasigna nilotinib could do even better and has more patent life.

Gleevec improved walking distance in a Phase III study in a very sick population of patients with PAH, and preclinical data suggest it may have a disease-modifying mechanism...